Intercept Pharmaceuticals, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“In animal models, INT-767 has shown the potential to both prevent and reverse organ damage due to fibrosis.” Read the following article
Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY. [Source: MarketWatch]
Company Website: https://interceptpharma.com